Managed by Brandon Capital, Brandon BioCatalyst supports the development and commercialisation of early-stage biomedical discoveries originating from member research organisations, providing both capital and expertise to guide the successful development of new therapies.
Brandon BioCatalyst is a unique collaboration of investors, CSL, government and more than 50 leading medical research institutes and hospitals united by a single purpose: generating cutting edge, next generation medical therapies and technologies to improve health and save lives.
50+ Medical research institutes and hospitals
ACT Government
NSW Government Health
Government of South Australia
Queensland Government
Victorian Government
Western Australian Government
Ministry of Business, Innovation & Employment (MBIE) NZ
Brandon Capital
Australian Government
Australian Super
Hesta
Host Plus
TelstraSuper
CSL
The Burnet Institute is an independent, not‐for‐profit Australian organization that is unique in its approach of linking medical research with public health action to address many of the major health problems affecting disadvantaged communities. This approach allows us to develop innovative health solutions ranging from the highly technological through to those that are community-based.
ViewThe Heart Research Institute (HRI) is an internationally recognised research institute that performs cutting-edge cardiovascular research. The main focus of this research is to gain an understanding of the development and progression of atherosclerosis, the dominant cause of cardiovascular disease.
View
Brandon Capital manages Brandon BioCatalyst, providing seed and venture capital investment to support the development and international growth of Australian and New Zealand life science companies.
Brandon Capital website
Through the internship it was fantastic to understand what Brandon are looking for in the projects they fund. The learnings from the internship program will be applied to the new projects we develop, both in reviewing the opportunity and developing a solid business plan that will increase the commercial success.
The internship was a valuable experience that filled a critical gap in my knowledge of how early-stage life science technologies are commercialised. Up to this point, my experience was from a technology development perspective, and I did not have a full understanding of what investors were seeking in potential investments. The internship experience is immeasurable and will pay dividends well into the future.
The internship was an excellent learning and development opportunity. I greatly improved my understanding of the venture capital financing model and elements such as valuation, due diligence, market analysis and drug development. The MRCF internship program also enabled me to expand my national commercialisation networks and work alongside experienced biotech investors.
